Biotech & Medicine
133 articles RSS
Revolution Medicines' Daily Pill Daraxonrasib Nearly Doubles Survival in Metastatic Pancreatic Cancer, Cutting Risk of Death by 60 Percent
Phase 3 RASolute 302 data show the oral RAS inhibitor extending median overall survival to 13.2 months versus 6.7 months on chemotherapy, sending Revolution Medicines shares up nearly 40 percent.
Connectome-seq Turns Brain Wiring into a Sequencing Problem, Mapping Thousands of Synaptic Connections with RNA Barcodes
University of Illinois researchers publish Connectome-seq in Nature Methods, using RNA barcodes to map over 1,000 neurons at single-synapse resolution and uncover previously unknown connectivity patterns in the mouse brain.
Berkeley's Innovative Genomics Institute Uses CRISPR to Boost Sorghum Photosynthesis Gene Expression More Than 30-Fold
Two companion Nature Biotechnology papers map over 30,000 CRISPR edits across sorghum's regulatory DNA, achieving unprecedented control over photosynthesis genes with implications for crop yields and carbon capture.
NIH-Funded Team Engineers a Miniature CRISPR Nuclease That Fits Inside Viral Vectors, Clearing a Major Hurdle for In Vivo Gene Therapy
UT Austin and Metagenomi researchers engineered Al3Cas12f RKK, a compact CRISPR enzyme that achieves over 80% editing efficiency while fitting inside AAV delivery vehicles.
Scientists Discover a Hidden Lymphatic Drainage Hub in the Human Brain, Rewriting the Map of Cerebral Waste Clearance
MRI imaging and tissue analysis reveal that the middle meningeal artery hosts an organized lymphatic network responsible for brain waste removal, with implications for Alzheimer's research.
Fecal Transplant Capsules Nearly Double Immunotherapy Response Rates Across Three Cancer Types in Phase I/II Trials
Two companion trials published in Nature Medicine show oral FMT capsules raised immunotherapy response rates to 80% in lung cancer and 75% in melanoma, while reducing toxic side effects in kidney cancer.
Ascendis Pharma Launches YUVIWEL in the US, Bringing the First Weekly Injection for Achondroplasia to Market with Seven-Year Orphan Exclusivity
The first once-weekly treatment for achondroplasia is now commercially available in the United States after Ascendis Pharma secured orphan drug exclusivity through 2033.
Largest TB Vaccine Trial in Decades Finds VPM1002 Halves Extrapulmonary Risk but Falls Short of Broad Protection
Phase 3 PreVenTB trial of 12,717 people across India shows VPM1002 cuts extrapulmonary tuberculosis by 50%, but neither candidate prevents pulmonary TB or latent infection.
Prime Medicine Seeks FDA Accelerated Approval for First-Ever Prime Editing Therapy After Two Patients Achieve Durable Immune Restoration
Prime Medicine is pursuing accelerated approval for PM359, an autologous prime editing therapy that restored immune function in both patients treated for chronic granulomatous disease, marking the first clinical use of prime editing technology.
UCSF and Berkeley Scientists Engineer CAR-T Cells Directly Inside the Body, Clearing Tumors in Mice With a Single Injection
A two-particle gene-editing system published in Nature creates functional CAR-T cells in vivo, eliminating the costly weeks-long manufacturing process and clearing leukemia, myeloma, and solid tumors in preclinical models.
McGill Researchers Map 38 Neuropeptide Receptors Across the Human Brain, Revealing How Ancient Signaling Molecules Shaped Higher Cognition
A Nature Neuroscience study from the Montreal Neurological Institute constructs the first whole-brain atlas of 14 neuropeptide families, uncovering a cortical-subcortical gradient and evidence that neuropeptide refinement coincided with the evolutionary emergence of the neocortex.
BioNTech's Personalized mRNA Vaccine Keeps 11 of 14 Triple-Negative Breast Cancer Patients Relapse-Free for Up to Six Years
A first-in-human trial published in Nature shows BioNTech's individualized neoantigen mRNA vaccine produces durable T cell immunity and sustained disease control in aggressive breast cancer.